Skip to content
Loading…
Biocon Executive Chairperson Kiran Mazumdar-Shaw told Bloomberg's Francine Lacqua that a wave of expiring biologic patents provides a major runway to expand affordable cancer biosimilars and elevate the company above its current top-five global ranking. Speaking on the sidelines…
To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.